Heart Test Laboratories Inc
For the period ended Apr 30, 2024. Filed Jul 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jul 29, 2024
HSCS$2.40-11.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of April 30, 2024 and 2023
Balance Sheets
| April 30, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $5,807,648 | $1,660,467 |
| Inventory, net | 629,179 | 676,359 |
| Prepaid expenses | 183,704 | 143,460 |
| Other current assets | 40,374 | 40,374 |
| Deferred offering costs | 692,988 | 175,921 |
| Total current assets | 7,353,893 | 2,696,581 |
| Property and equipment, net | 97,991 | 61,428 |
| Intangible assets, net | 1,589,246 | — |
| Right-of-use assets, net | 461,983 | 529,224 |
| TOTAL ASSETS | $9,503,113 | $3,287,233 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $448,183 | $631,369 |
| Accrued expenses | 398,331 | 385,857 |
| Accrued interest expense | 268,813 | 237,534 |
| Operating lease liabilities, current portion | 102,293 | 29,535 |
| Current portion of notes payable | 500,000 | 500,000 |
| Other current liabilities | 34,147 | 48,596 |
| Total current liabilities | 1,751,767 | 1,832,891 |
| LONG-TERM LIABILITIES | ||
| Notes payable | — | 500,000 |
| Accrued expenses | — | 187,450 |
| Operating lease liabilities, long-term portion | 434,045 | 536,335 |
| Total long-term liabilities | 434,045 | 1,223,785 |
| TOTAL LIABILITIES | 2,185,812 | 3,056,676 |
| COMMITMENTS AND CONTINGENCIES (NOTE 2, 4-6, and 8) | ||
| STOCKHOLDERS EQUITY | ||
| Series A, B, and C convertible preferred stock, $0.001 par value, 20,000,000 shares authorized and 620,000 designated; 380,440 shares issued and outstanding as of April 30, 2024 and 380,871 shares issued and outstanding as of April 30, 2023. | 380 | 381 |
| Common Stock, $0.001 par value, 500,000,000 shares authorized; 676,598 shares issued and outstanding as of April 30, 2024 and 101,332 shares issued and outstanding as of April 30, 2023. | 677 | 101 |
| Additional paid-in capital | 74,678,650 | 60,987,273 |
| Accumulated deficit | (67,362,406) | (60,757,198) |
| TOTAL STOCKHOLDERS EQUITY | 7,317,301 | 230,557 |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $9,503,113 | $3,287,233 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.